Archives

Sarepta Therapeutics reports sustained functional improvement two years after treatment with SRP-9001, its investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy. [...]

La Force is happy to share the latest edition of the Catabasis Connection newsletter – Communicating clinical trial results. Catabasis understands the importance of clearly communicating [...]

Santhera exercises option to obtain worldwide rights of Vamorolone for Duchenne muscular dystrophy (DMD) and All Other Indications La Force is happy to share this press release provided [...]

Learning that your son has Duchenne muscular dystrophy (DMD) is watching your child lose his muscular ability month after month. This is Jean-Philippe Morand’s reality: his son Victor is [...]